StonvexLoading…
StonvexStonvexStonvexCore line items from PATH's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2026 2026-01-31 | Annual 2025 2025-01-31 | Annual 2024 2024-01-31 | Annual 2023 2023-01-31 |
|---|---|---|---|---|
Revenue | $1.61B | $1.43B | $1.31B | $1.06B |
Operating Income | $56.76M | $-162.57M | $-164.72M | $-348.28M |
Net Income | $282.33M | $-73.69M | $-89.88M | $-328.35M |
EPS (Diluted) | $0.52 | $-0.13 | $-0.16 | $-0.60 |
Total Assets | $3.18B | $2.87B | $2.95B | $2.74B |
Total Liabilities | $1.10B | $1.02B | $938.64M | $815.05M |
Cash & Equivalents | $871.16M | $879.20M | $1.06B | $1.40B |
Free Cash Flow OCF − CapEx | $352.16M | $305.64M | $291.74M | $-33.80M |
Shares Outstanding | 544.86M | 559.93M | 563.86M | 548.02M |